Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
5.10
+0.27 (5.59%)
At close: Sep 26, 2025, 4:00 PM EDT
5.13
+0.03 (0.59%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Vanda Pharmaceuticals Revenue
Vanda Pharmaceuticals had revenue of $52.59M in the quarter ending June 30, 2025, with 4.19% growth. This brings the company's revenue in the last twelve months to $203.47M, up 11.78% year-over-year. In the year 2024, Vanda Pharmaceuticals had annual revenue of $198.77M with 3.18% growth.
Revenue (ttm)
$203.47M
Revenue Growth
+11.78%
P/S Ratio
1.47
Revenue / Employee
$552,899
Employees
368
Market Cap
301.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 198.77M | 6.13M | 3.18% |
| Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
| Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
| Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
| Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VNDA News
- 2 days ago - Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" - PRNewsWire
- 4 weeks ago - Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement - Seeking Alpha
- 4 weeks ago - Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences - PRNewsWire
- 4 weeks ago - Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera - PRNewsWire
- 5 weeks ago - Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz® - PRNewsWire
- 5 weeks ago - In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder - PRNewsWire
- 2 months ago - Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results - PRNewsWire